Literature DB >> 14582450

Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.

Erding Hu1, Dennis Lee.   

Abstract

RhoA and Rho-kinase (ROCK) participate in diverse cellular signaling functions such as smooth muscle contraction, cytoskeleton rearrangement, and cell migration and proliferation. In smooth muscle, ROCK plays an important role in calcium sensitization, an event that controls vascular vessel tone. Recent studies using ROCK inhibitors along with cellular and molecular biology techniques have revealed a pivotal role of this enzyme in many other aspects of cardiovascular function. This review will focus on the current understanding of Rho/ROCK signaling pathways and discuss the use of ROCK inhibitors as therapeutic agents for cardiovascular diseases ranging from hypertension to atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582450

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  4 in total

1.  End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.

Authors:  Matthias Löhn; Oliver Plettenburg; Aimo Kannt; Markus Kohlmann; Armin Hofmeister; Dieter Kadereit; Peter Monecke; Alexander Schiffer; Anke Schulte; Hartmut Ruetten; Yuri Ivashchenko
Journal:  World J Cardiol       Date:  2015-01-26

Review 2.  Remnant lipoproteins and atherosclerosis.

Authors:  ThB Twickler; G M Dallinga-Thie; M J Chapman; J S Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

3.  Targeted disruption of ROCK1 causes insulin resistance in vivo.

Authors:  Dae Ho Lee; Jianjian Shi; Nam Ho Jeoung; Min Seon Kim; Janice M Zabolotny; Sam W Lee; Morris F White; Lei Wei; Young-Bum Kim
Journal:  J Biol Chem       Date:  2009-03-10       Impact factor: 5.157

4.  Immunohistochemical analysis of target proteins of Rho-kinase in a mouse model of accelerated atherosclerosis.

Authors:  Mark Rekhter; Kaarthik Chandrasekhar; Donetta Gifford-Moore; Xiao-di Huang; Pamela Rutherford; Jeffrey Hanson; Raymond Kauffman
Journal:  Exp Clin Cardiol       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.